Skip to Content

Join the 'Humira' group to help and get support from people like you.

Humira News

California Sues Drug Maker AbbVie for Allegedly Paying Doctors to Prescribe Humira

Posted 20 Sep 2018 by Drugs.com

A lawsuit filed Tuesday in California claims that pharmaceutical company AbbVie used cash, gifts, and services to induce doctors to overprescribe the widely used drug Humira, ignoring the medicine's potentially lethal side effects. Speaking in a conference call to announce the lawsuit, California Insurance Commissioner Dave Jones said the alleged scheme meant that in many cases physicians ...

FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira

Posted 30 Aug 2017 by Drugs.com

Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: moderate to severe active rheumatoid arthritis moderate to severe polyarticular juvenile idiopathic arthritis** a ...

Early Treatment Equals Better Results for Rheumatoid Arthritis

Posted 25 Apr 2017 by Drugs.com

TUESDAY, April 25, 2017 – Treating rheumatoid arthritis early may make for better outcomes, a new study suggests. Patients who were treated within six months of developing the first signs of the autoimmune disease did better in the long run and were less likely to suffer early death, British researchers found. The findings stem from an analysis of more than 600 patients who were initially ...

New Meds Make Inroads Against Crohn's Disease

Posted 13 Apr 2017 by Drugs.com

THURSDAY, April 13, 2017 – Fewer Americans with Crohn's disease are ending up in the hospital than in the past, according to a new federal study. Crohn's is a chronic inflammatory bowel disorder that often leads to surgery for most with the disease. Hospitalization rates for Crohn's disease remained stable in the United States between 2003 and 2013. That's a change from a study done from 1998 to ...

Could a Germ Link Gum Disease, Rheumatoid Arthritis?

Posted 15 Dec 2016 by Drugs.com

THURSDAY, Dec. 15, 2016 – A specific germ may help explain the long-noticed connection between gum disease and rheumatoid arthritis, a new study suggests. The discovery might also point to the potential origins of the painful joint illness. "If we're right, this will totally change the view of rheumatoid arthritis and treatment of patients," said study co-author Dr. Felipe Andrade. But, Andrade, ...

Drug Stelara May Ease Crohn's Disease

Posted 18 Nov 2016 by Drugs.com

THURSDAY, Nov. 17, 2016 – People with moderate to severe Crohn's disease who haven't responded to other treatments may benefit from the drug ustekinumab (Stelara), a new study suggests. Stelara is a monoclonal antibody that blocks the action of the inflammatory agents interleukin-12 and interleukin-23. The drug had been approved for the treatment of psoriasis and is now approved for treating ...

Study Identifies Genetic Subtypes of Crohn's Disease

Posted 14 Oct 2016 by Drugs.com

FRIDAY, Oct. 14, 2016 – Crohn's disease appears to have at least two distinct genetic subtypes, which could explain why the condition is so hard to treat, a new study suggests. "The one-treatment-fits-all approach doesn't seem to be working for Crohn's patients," said study co-senior author Dr. Shehzad Sheikh. He's an assistant professor in the departments of medicine and genetics at the ...

Amjevita Approved to Treat Inflammatory Diseases

Posted 27 Sep 2016 by Drugs.com

MONDAY, Sept. 26, 2016 – Amjevita (adalimumab-atto) – a biosimilar drug similar to the popular anti-inflammatory drug Humira – has been approved by the U.S. Food and Drug Administration. Amjevita has been approved for moderate-to-severe rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis (an arthritis that affects the spine); Crohn's disease; ulcerative colitis; plaque psoriasis ...

FDA Approves Amjevita (adalimumab-atto), a Biosimilar to Humira

Posted 26 Sep 2016 by Drugs.com

September 23, 2016 – The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved for the following indications in adult patients: moderately to severely active rheumatoid arthritis; active psoriatic arthritis; active ankylosing spondylitis (an arthritis that affects the spine); ...

Immune-Based Drug May Ease Chronic Eye Condition

Posted 8 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 7, 2016 – People with chronic eye inflammation known as uveitis may be able to keep the condition at bay with the immune-suppressing drug Humira (adalimumab), a new study finds. "Humira doesn't cure uveitis, but it does cause it to become quiet," said lead researcher Dr. Glenn Jaffe. He's a professor of ophthalmology at Duke University School of Medicine in Durham, N.C., and a ...

New Treatments Helping Kids With Juvenile Arthritis

Posted 20 Jul 2016 by Drugs.com

WEDNESDAY, July 20, 2016 – New treatments for juvenile arthritis offer hope to children with the chronic autoimmune condition, doctors say. Scientists are still working to understand what causes juvenile arthritis and how to stop its progression. But, kids coping with its effects have reason to be optimistic, according to Dr. Nikolay Nikolov, a rheumatologist and clinical team leader at the U.S. ...

AbbVie's Humira (adalimumab) Receives FDA Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis

Posted 2 Jul 2016 by Drugs.com

NORTH CHICAGO, Ill., June 30, 2016 /PRNewswire/ – AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Humira (adalimumab) for the treatment of non-infectious intermediate, posterior and panuveitis. Humira is now the first and only FDA-approved non-corticosteroid therapy available for adults with non-infectious ...

FDA Approves Humira (adalimumab) for Moderate to Severe Hidradenitis Suppurativa

Posted 11 Sep 2015 by Drugs.com

NORTH CHICAGO, Ill., Sept. 10, 2015 /PRNewswire/ – AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Humira (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS). Humira is now the first and only FDA-approved therapy for adults with HS. Hidradenitis suppurativa is a chronic inflammatory ...

Experimental Psoriasis Drug Shows Promise

Posted 8 Jul 2015 by Drugs.com

WEDNESDAY, July 8, 2015 – Preliminary trial results suggest that an experimental psoriasis drug may control the chronic skin disease better than the current standard treatment. The drug, guselkumab, was compared to the commonly used medication adalimumab (Humira, Enbrel) in a study involving nearly 300 patients with plaque psoriasis. Up to 86 percent of patients who received guselkumab cleared ...

Gene Discoveries Could Help Rheumatoid Arthritis Treatment

Posted 28 Apr 2015 by Drugs.com

TUESDAY, April 28, 2015 – Genetic variations may hold clues to rheumatoid arthritis – suggesting not only who will develop the painful condition, but also predicting its severity and even who might die from it, a new study says. "Genetic factors predisposing to disease, to disease severity, and response to treatment will allow tailoring treatment to individual patients' needs," said lead ...

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Ankylosing Spondylitis, Crohn's Disease - Maintenance, Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Crohn's Disease - Acute, Hidradenitis Suppurativa, Juvenile Idiopathic Arthritis, Plaque Psoriasis, Psoriasis, Spondyloarthritis, Ulcerative Colitis

Humira Patient Information at Drugs.com